References
1. Bostock J. Case of a Periodical Affection of the Eyes and Chest.Med Chir Trans. 1819;10(Pt 1):161-165.
2. Bostock J. Of the catarrhus aestivus, or summer catarrh. Med
Chir Trans. 1828;14:437-446.
3. Bachmann MF, Kundig TM. Allergen-specific immunotherapy: is it
vaccination against toxins after all? Allergy. 2017;72(1):13-23.
4. Ishizaka K, Ishizaka T. Identification of γE-Antibodies as a Carrier
of Reaginic Activity1. The Journal of Immunology.1967;99(6):1187-1198.
5. Johansson SG, Bennich H, Wide L. A new class of immunoglobulin in
human serum. Immunology. 1968;14(2):265-272.
6. Till S. Immunotherapy: readdressing the balance between TH2 and TH1
cells. In. Vol 27: Wiley Online Library; 1997:981-985.
7. Celebi Sozener Z, Mungan D, Cevhertas L, Ogulur I, Akdis M, Akdis C.
Tolerance mechanisms in allergen immunotherapy. Curr Opin Allergy
Clin Immunol. 2020;20(6):591-601.
8. Belliveau PP. Omalizumab: a monoclonal anti-IgE antibody.MedGenMed. 2005;7(1):27.
9. Flicker S, Linhart B, Wild C, Wiedermann U, Valenta R. Passive
immunization with allergen-specific IgG antibodies for treatment and
prevention of allergy. Immunobiology. 2013;218(6):884-891.
10. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited.Current opinion in allergy and clinical immunology.2004;4(4):313-318.
11. LaHood NA, Min J, Keswani T, et al. Immunotherapy-induced
neutralizing antibodies disrupt allergen binding and sustain allergen
tolerance in peanut allergy. J Clin Invest. 2023;133(2).
12. Orengo JM, Radin AR, Kamat V, et al. Treating cat allergy with
monoclonal IgG antibodies that bind allergen and prevent IgE engagement.Nat Commun. 2018;9(1):1421.
13. Storni F, Zeltins A, Balke I, et al. Vaccine against peanut allergy
based on engineered virus-like particles displaying single major peanut
allergens. J Allergy Clin Immunol. 2020;145(4):1240-1253 e1243.
14. Schmitz N, Dietmeier K, Bauer M, et al. Displaying Fel d1 on
virus-like particles prevents reactogenicity despite greatly enhanced
immunogenicity: a novel therapy for cat allergy. J Exp Med.2009;206(9):1941-1955.
15. Fernández-Quintero ML, Pomarici ND, Math BA, et al. Antibodies
exhibit multiple paratope states influencing VH–VL domain orientations.Communications biology. 2020;3(1):1-14.
16. Link A, Zabel F, Schnetzler Y, Titz A, Brombacher F, Bachmann MF.
Innate immunity mediates follicular transport of particulate but not
soluble protein antigen. The Journal of Immunology.2012;188(8):3724-3733.
17. Salzmann M, Bachmann M. Estimation of maximal affinities between
T-cell receptors and MHC\peptide complexes.Molecular immunology. 1998;35(2):65-71.
18. Edidin M. Fluorescent labeling of cell surfaces. Methods in
Cell Biology. 1988;29:87-102.
19. Chang X, Zha L, Wallimann A, et al. Low‐affinity but high‐avidity
interactions may offer an explanation for IgE‐mediated allergen
cross‐reactivity. Allergy. 2021;76(8):2565-2574.
20. Möbs C, Ipsen H, Mayer L, et al. Birch pollen immunotherapy results
in long-term loss of Bet v 1–specific TH2 responses, transient TR1
activation, and synthesis of IgE-blocking antibodies. Journal of
Allergy and Clinical Immunology. 2012;130(5):1108-1116. e1106.
21. Zha L, Leoratti FMS, He L, et al. An unexpected protective role of
low-affinity allergen-specific IgG through the inhibitory receptor
FcgammaRIIb. J Allergy Clin Immunol. 2018;142(5):1529-1536 e1526.
22. Uermosi C, Zabel F, Manolova V, et al. IgG-mediated down-regulation
of IgE bound to mast cells: a potential novel mechanism of
allergen-specific desensitization. Allergy. 2014;69(3):338-347.
23. Strelow J, Dewe W, Iversen PW, et al. Mechanism of action assays for
enzymes. Assay Guidance Manual [Internet]. 2012.
24. Sobczak J, Krenger P, Storni F, et al. The next generation
virus-like particle platform for the treatment of peanut allergy.Allergy. 2023;in press.
25. Storni F, Cabral-Miranda G, Roesti E, et al. A Single Monoclonal
Antibody against the Peanut Allergen Ara h 2 Protects against Systemic
and Local Peanut Allergy. Int Arch Allergy Immunol.2020;181(5):334-341.
26. Schmitz N, Dietmeier K, Bauer M, et al. Displaying Fel d1 on
virus-like particles prevents reactogenicity despite greatly enhanced
immunogenicity: a novel therapy for cat allergy. Journal of
Experimental Medicine. 2009;206(9):1941-1955.
27. Zinkhan S, Thoms F, Sousa Augusto GA, Vogel M, Bachmann M. On the
role of allergen-specific IgG subclasses for blocking human basophil
activation. Frontiers in immunology. 2022;13(892631).
28. Shamji MH, Kappen JH, Akdis M, et al. Biomarkers for monitoring
clinical efficacy of allergen immunotherapy for allergic
rhinoconjunctivitis and allergic asthma: an EAACI Position Paper.Allergy. 2017;72(8):1156-1173.
29. Reisinger J, Horak F, Pauli G, et al. Allergen-specific nasal IgG
antibodies induced by vaccination with genetically modified allergens
are associated with reduced nasal allergen sensitivity. Journal of
allergy and clinical immunology. 2005;116(2):347-354.
30. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size,
geometry, kinetics and molecular patterns. Nature Reviews
Immunology. 2010;10(11):787-796.
31. Chang X, Krenger P, Krueger CC, et al. TLR7 Signaling shapes and
maintains antibody diversity upon virus-like particle immunization.Frontiers in immunology. 2021;12.